Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691923 · ClinicalTrials.gov registry record · Phase 2
Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker
A Phase 2 study of Brain Cancer, sponsored by David W. Roberts.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02691923 is a Phase 2 study of Brain Cancer that is actively recruiting participants, run by David W. Roberts. The registered enrollment target is 30 participants, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02691923, a Phase 2 study of Brain Cancer, is actively recruiting participants, sponsored by David W. Roberts.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical research will evaluate the diagnostic potential of fluorescein as visualized through an operating microscope relative to 1) contrast enhancement on co-registered preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard histology obtained from biopsy sampling during the procedure. Subjects will include those people with operable brain tumor with first-time presumed pre-surgical diagnosis of high-grade glioma or low-grade glioma.
Conditions Studied
Interventions
- DRUG Fluorescein
- DRUG Fluorescein + ALA
Study Locations (1)
New Hampshire
- Sally B Mansur - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02691923
The ClinicalTrials.gov registry entry for NCT02691923 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 507-participant average among 47 other Brain Cancer trials with a reported enrollment target (94% lower). The listed sponsor is David W. Roberts, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fluorescein is the first listed.
NCT02691923 reports 1 study location spanning 1 distinct geographic area - top geographies include New Hampshire.
Frequently Asked Questions
What is clinical trial NCT02691923 about?
NCT02691923 is a clinical study titled "Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker". This clinical research will evaluate the diagnostic potential of fluorescein as visualized through an operating microscope relative to 1) contrast enhancement on co-registered preoperative MR scans, 2) intraoperative ALA-induced PpIX fluorescence and 3) gold-standard histology obtained from biopsy s...
What is the current status of trial NCT02691923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2016-03. Estimated completion is 2026-12.
What conditions does trial NCT02691923 study?
This clinical trial studies the following conditions: Brain Cancer.
What interventions are being tested in trial NCT02691923?
The interventions under investigation include: Fluorescein (DRUG), Fluorescein + ALA (DRUG).
Who is sponsoring clinical trial NCT02691923?
This trial is sponsored by David W. Roberts, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02691923 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
RECRUITING · Phase 2
-
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.